Beers Michael F, Mulugeta Surafel
Pulmonary, Allergy, and Critical Care Division, Department of Medicine, Surfactant Biology Laboratories, University of Pennsylvania Perelman School of Medicine, Edward J. Stemmler Hall, Suite 218, 3450 Hamilton Walk, Philadelphia, PA 19104, USA.
Cell Tissue Res. 2017 Mar;367(3):481-493. doi: 10.1007/s00441-016-2554-z. Epub 2016 Dec 26.
The lipid transporter, ATP-binding cassette class A3 (ABCA3), is a highly conserved multi-membrane-spanning protein that plays a critical role in the regulation of pulmonary surfactant homeostasis. Mutations in ABCA3 have been increasingly recognized as one of the causes of inherited pulmonary diseases. These monogenic disorders produce familial lung abnormalities with pathological presentations ranging from neonatal surfactant-deficiency-induced respiratory failure to childhood or adult diffuse parenchymal lung diseases for which specific treatment modalities remain limited. More than 200 ABCA3 mutations have been reported to date with approximately three quarters of patients presenting as compound heterozygotes. Recent advances in our understanding of the molecular basis underlying normal ABCA3 biosynthesis and processing and of the mechanisms of alveolar epithelial cell dysregulation caused by the expression of its mutant forms are beginning to emerge. These insights and the role of environmental factors and modifier genes are discussed in the context of the considerable variability in disease presentation observed in patients with identical ABCA3 gene mutations. Moreover, the opportunities afforded by an enhanced understanding of ABCA3 biology for targeted therapeutic strategies are addressed.
脂质转运蛋白ATP结合盒A3(ABCA3)是一种高度保守的多跨膜蛋白,在肺表面活性物质稳态调节中起关键作用。ABCA3突变日益被认为是遗传性肺部疾病的病因之一。这些单基因疾病会导致家族性肺部异常,病理表现从新生儿表面活性物质缺乏引起的呼吸衰竭到儿童或成人弥漫性实质性肺部疾病不等,而针对这些疾病的具体治疗方法仍然有限。迄今为止,已报道了200多种ABCA3突变,约四分之三的患者表现为复合杂合子。我们对正常ABCA3生物合成和加工的分子基础以及由其突变形式表达引起的肺泡上皮细胞失调机制的理解,最近开始有了进展。在具有相同ABCA3基因突变的患者中观察到的疾病表现存在相当大的变异性的背景下,讨论了这些见解以及环境因素和修饰基因的作用。此外,还探讨了对ABCA3生物学的深入理解为靶向治疗策略带来的机遇。